ConductScience.org, home

Paper42701351

The Evolution of Medications for Obesity Management.

Gill J and 1 other. JGH Open, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The Evolution of Medications for Obesity Management. Papers, record 42701351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42701351

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Evolution of Medications for Obesity Management.
PubMed
Journal
JGH Open
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-07
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gill JJaskirath
2Sumithran PPriyahttps://orcid.org/0000-0002-9576-1050

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References85

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140544433Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.N Engl J Med2025https://conductscience.org/library/papers/40544433PubMed
240960239Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.N Engl J Med2025https://conductscience.org/library/papers/40960239PubMed
318095746Orlistat-associated adverse effects and drug interactions: a critical review.Drug Saf2008https://conductscience.org/library/papers/18095746PubMed
437796527Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.JAMA2023https://conductscience.org/library/papers/37796527PubMed
541018564Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions.Obes Pillars2025https://conductscience.org/library/papers/41018564PubMed
642418774Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.N Engl J Med2026https://conductscience.org/library/papers/42418774PubMed
738829659Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?JAMA2024https://conductscience.org/library/papers/38829659PubMed
822822160Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice.Endocrinology2012https://conductscience.org/library/papers/22822160PubMed
933137293Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.Lancet Diabetes Endocrinol2020https://conductscience.org/library/papers/33137293PubMed
1041138739Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.Lancet2025https://conductscience.org/library/papers/41138739PubMed
1142252333Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med2026https://conductscience.org/library/papers/42252333PubMed
1220673995Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2010https://conductscience.org/library/papers/20673995PubMed
1340450457
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.
Am J Clin Nutr2025https://conductscience.org/library/papers/40450457PubMed
1439476339Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J Med2024https://conductscience.org/library/papers/39476339PubMed
1522915024Anti-obesity drugs: past, present and future.Dis Model Mech2012https://conductscience.org/library/papers/22915024PubMed
1637934220Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.JAMA2023https://conductscience.org/library/papers/37934220PubMed
1721481449
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Lancet2011https://conductscience.org/library/papers/21481449PubMed
1831750601Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.Diabetes Obes Metab2020https://conductscience.org/library/papers/31750601PubMed
1940804463Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.Int J Obes (Lond)2025https://conductscience.org/library/papers/40804463PubMed
2037881914Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.Ann Pharmacother2024https://conductscience.org/library/papers/37881914PubMed

See all 85 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42701351

GET https://conductscience.org/api/papers/v1/42701351/references?page=2